JSM 2011 Online Program

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.

Activity Details

423 Tue, 8/2/2011, 2:00 PM - 3:50 PM CC-Hall D
Contributed Oral Poster Presentations: Biopharmaceutical Section — Contributed Poster Presentations
Biopharmaceutical Section
Chair(s): Benmei Liu, National Cancer Institute
01: A Joint Model for Tumor Burden and Progression-Free Survival Aparna B. Anderson, Bristol-Myers Squibb ; Ye Shen, Yale University School of Public Health ; Ritwik Sinha, Hewlett Packard Laboratories India
02: Reinforcement Learning Strategies for Clinical Trials in Non-Small Cell Lung Cancer Yufan Zhao, Amgen Inc.
03: Evaluation of Power and Type I Error on Different Statistical Methods Analyzing Hypoglycemia Data Using Bootstrap Simulation Honghua Jiang, Eli Lilly and Company ; William Huster, Eli Lilly and Company ; Xiao Ni , Eli Lilly and Company
04: Estimating Controlled Direct Effects for Time-Varying Treatments Using Structural Nested Mean Models Tomohiro Shinozaki, The University of Tokyo ; Yutaka Matsuyama, The University of Tokyo ; Yasuo Ohashi, The University of Tokyo
05: The Ratio of Median or Mean Change Scores for Treatment Comparisons Joseph T. Wang, Pfizer Inc. ; Kelly H. Zou, Pfizer Inc. ; Martin Ove Carlsson, Pfizer Inc.
06: Sample Size Calculations in Clinical Trials with Binary Data: Theoretical and Practical Issues Arminda Siqueira, Universidade Federal de Minas Gerais
07: Predict the Probability of Final Trial Success in Interim Analysis Rujun Teng, Merck & Co., Inc. ; Kaifeng Lu, Forest Laboratories, Inc.
08: Using Z-Prime Factor as Quantitative Measure of In Vivo PD Assay Quality Winnie Weng, Amgen Inc. ; Guang Chen, Amgen Inc. ; Margaret Weidner, Amgen Inc. ; Kathy Keegan, Amgen Inc. ; Christophe Queva, Amgen Inc.
09: Analysis of GEF-Mediated Nucleotide Exchange Assay Experiments Qinghua Song, Genentech Inc. ; Lindsay Garrenton, Genentech Inc. ; Imola Fodor, Genentech Inc. ; Guowei Fang, Genentech Inc. ; Peter Jackson, Genentech Inc.
10: Using Reinforcement Learning Strategies to Discover the Optimal Treatment for Advanced Colorectal Cancer Patients Zheng Ren, The University of North Carolina at Chapel Hill ; Michael R. Kosorok, The University of North Carolina at Chapel Hill
11: A Distribution-Free Bayesian Method for Estimating the Probability of Response in Combination Drug Tests John W. Seaman III, Alcon Laboratories, Inc. ; John W. Seaman Jr., Baylor University ; James Stamey, Baylor University
12: An Application of Group Sequential Method for Demonstration of Efficacy in Diagnostic Imaging Development Gajanan Bhat, Lantheus Medical Imaging, Inc. ; Jeffrey Joseph, Omnicare Clinical Research, Inc. ; Dana Washburn, Lantheus Medical Imaging, Inc.
13: Study Design of a Drug-Drug Interaction Trial Using Group Sequential Methods Wei Zhang, Eli Lilly and Company
14: A Comparison of Methods for Adjusting for the Baseline Measure Martin Ove Carlsson, Pfizer Inc. ; Kelly H. Zou, Pfizer Inc. ; Ching-Ray Yu, Pfizer Inc. ; Franklin W. Sun, Pfizer Inc.
15: Direct Cost of Schizophrenia in Quebec, Canada: An Incidence-Based Microsimulation Monte Carlo Markov Model Alice Dragomir, University of Montreal ; Jean-Eric Tarride, McMaster University ; Ridha Joober, McGill University ; Guy Rouleau, University of Montreal ; Sylvie Perreault, University of Montreal
16: Evaluation of Power of Different Cox Proportional Hazards Models Incorporating Stratification Factors — Moumita Sinha, Biocon Ltd. ; Shanshan Ding, University of Minnesota
17: Stratified Two-Sample Tests on the Change Scores When the Outcomes Are Correlated Between Baseline and Post-Treatment: A Simulation Study Using Bivariate Data — Ching-Ray Yu, Pfizer Inc. ; Martin Ove Carlsson, Pfizer Inc. ; Kelly H. Zou, Pfizer Inc.
18: Leveraging Baseline Information to Improve Inference in Adaptive Randomized Experiments with Small Sample Size Po-Han Brian Chen, The Johns Hopkins University ; Rosenblum Michael, The Johns Hopkins University
19: Evaluating Oncology Phase I Dose-Finding Study Designs — Lindsey Lian, PPD ; Hui Liu, PPD ; Jenny Huang, PPD
20: The VACS Risk Index Responds to Treatment Interventions and Is Highly Correlated with and Predictive of Mortality Events in the Optima Study Katherine Anne Kirkwood, VA Cooperative Studies Program ; Tassos Kyriakides, VA Cooperative Studies Program ; Sheldon T. Brown, James J. Peters VA Medical Center ; Amy C. Justice, VA Connecticut Healthcare System, West Haven ; Mark Holodniy, VA Palo Alto Healthcare System ; Janet Tate, VA Connecticut Healthcare System, West Haven ; Joseph Goulet, VA Connecticut Healthcare System, West Haven
21: Subgroup Discovery Showing Maximum Difference Between Treatment and Control Using Modified Patient Rule Induction Method (M-PRIM) Daniel Parks, GlaxoSmithKline ; Xiwu Lin, GlaxoSmithKline ; Kwan Lee, GlaxoSmithKline
22: A Phase II/III Randomized Clinical Trial Design with Sequential Decision Rule Based on Multiple Primary Endpoints Qian Shi, Mayo Clinic ; Daniel J. Sargent, Mayo Clinic
23: One-sided Upper Tolerance Limits for Longitudinal Data Judy X. Li, U.S. Food and Drug Administration ; Oscar Chiesa, U.S. Food and Drug Administration ; Min Zhu, SAS Institute Inc.
24: Evaluation of Different Numbers of Dilution Serials of Biological Samples Tested in Cell-Based Functional Assays Liping Song, Merck & Co., Inc. ; Robert Capen, Merck & Co., Inc.
25: Quantification of Impact of Safety Monitoring on Type I Error and Power of Efficacy Analysis in Phase III Group Sequential Clinical Trial Yanqiu Weng, Medical University of South Carolina ; Wenle Zhao, Medical University of South Carolina ; Yuko Palesch, Medical University of South Carolina

2011 JSM Online Program Home

For information, contact jsm@amstat.org or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.